Researchers concluded aspirin is a cost-effective prophylactic measure for patients who do not have a history of venous thromboembolism undergoing total joint arthroplasty compared to low-molecular-weight heparin, although patient age may factor into using aspirin after total knee arthroplasty. Using aspirin for [venous thromboembolism] VTE prophylaxis may be a reasonable, cost-effective strategy for individuals with no history of VTE following total hip arthroplasty and for those who are 80 years of age and older following total knee arthroplasty,” John T. Schousboe, MD, PhD, and colleagues wrote in the study. “For individuals younger than 80 years of age undergoing total knee arthroplasty, the most cost-effective strategy to prevent VTE events is uncertain.”
Schousboe and colleagues used a 1-month Markhov model for their study. Patients were considered healthy, having no post-phlebitic or post-phlebitic syndrome after VTE or had survived an intracranial hemorrhage after VTE. The researchers compared treatment 14 days after total hip arthroplasty (THA) and total knee arthroplasty (TKA) with 160 mg of aspirin or low-molecular-weight heparin in patients who were aged 55 years, 60 years, 65 years, 70 years, 75 years, 80 years and 85 years, according to the abstract.
The full article is located at Healio